Literature DB >> 30075337

Identification of Inpatient Allergic Drug Reactions Using ICD-9-CM Codes.

Rebecca R Saff1, Yu Li2, Nikita Santhanakrishnan3, Carlos A Camargo4, Kimberly G Blumenthal5, Li Zhou6, Aleena Banerji7.   

Abstract

BACKGROUND: The study of allergic drug reactions has been limited because of challenges in identifying and confirming cases.
OBJECTIVE: To determine the utility of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for identifying inpatient allergic drug reactions and to compare findings with previous data in the emergency department.
METHODS: By reviewing medical records of inpatients with ICD-9-CM codes and E codes suggestive of allergic drug reactions at a large urban academic medical center, we determined codes that yielded the most drug allergy cases and identified culprit drugs.
RESULTS: In 2005 and 2010, 3337 and 5282 possible allergic drug reactions during hospitalization were identified and 1367 were reviewed. Allergic drug reactions were found in 409 (30.1%) of the reviewed charts, with 172 (29.7%) in 2005 and 237 (30.5%) in 2010. The codes that identified the highest percentage of true allergic drug reactions were dermatitis due to drug (693.0), allergic urticaria (708), angioneurotic edema (995.1), and anaphylaxis (995.0). Antibiotics were the most common cause (44.4%); however, multiple drug classes were often identified as likely culprit drugs.
CONCLUSION: Specific ICD-9-CM codes can identify patients with allergic drug reactions, with antibiotics accounting for almost half of true reactions. Most patients with codes 693.0, 995.1, 708, and 995.0 had allergic drug reactions, with 693.0 as the highest yield code. An aggregate of multiple specific codes consistently identifies a cohort of patients with confirmed allergic drug reactions.
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adverse drug reactions; Clinical Modification (ICD-9-CM) codes; Drug allergy; Drug hypersensitivity; Epidemiology; International Classification of Diseases; Ninth Revision

Mesh:

Substances:

Year:  2018        PMID: 30075337     DOI: 10.1016/j.jaip.2018.07.022

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  6 in total

1.  Natural Language Processing Combined with ICD-9-CM Codes as a Novel Method to Study the Epidemiology of Allergic Drug Reactions.

Authors:  Aleena Banerji; Kenneth H Lai; Yu Li; Rebecca R Saff; Carlos A Camargo; Kimberly G Blumenthal; Li Zhou
Journal:  J Allergy Clin Immunol Pract       Date:  2019-12-16

2.  Adverse Drug Events Related to Common Asthma Medications in US Hospitalized Children, 2000-2016.

Authors:  Luyu Xie; Andrew Gelfand; Matthew S Mathew; Folefac D Atem; Nimisha Srikanth; George L Delclos; Sarah E Messiah
Journal:  Drugs Real World Outcomes       Date:  2022-06-08

Review 3.  The Use of Electronic Health Records to Study Drug-Induced Hypersensitivity Reactions from 2000 to 2021: A Systematic Review.

Authors:  Fatima Bassir; Sheril Varghese; Liqin Wang; Yen Po Chin; Li Zhou
Journal:  Immunol Allergy Clin North Am       Date:  2022-03-31       Impact factor: 3.152

4.  Trends in Emergency Department Visits and Hospitalizations for Acute Allergic Reactions and Anaphylaxis Among US Older Adults: 2006-2014.

Authors:  Anna Chen Arroyo; Lacey B Robinson; Rebecca E Cash; Mohammad Kamal Faridi; Kohei Hasegawa; Carlos A Camargo
Journal:  J Allergy Clin Immunol Pract       Date:  2021-03-30

5.  Allergic Reactions in Two Academic Medical Centers.

Authors:  Neelam A Phadke; Li Zhou; Christian M Mancini; Jie Yang; Paige Wickner; Xiaoqing Fu; Kimberly G Blumenthal
Journal:  J Gen Intern Med       Date:  2020-09-21       Impact factor: 6.473

6.  Antibiotic Use in Patients With β-Lactam Allergies and Pneumonia: Impact of an Antibiotic Side Chain-Based Cross-Reactivity Chart Combined With Enhanced Allergy Assessment.

Authors:  Curtis D Collins; Renee S Bookal; Anurag N Malani; Harvey L Leo; Tara Shankar; Caleb Scheidel; Nina West
Journal:  Open Forum Infect Dis       Date:  2021-11-17       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.